Conditions: HCV Infection
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 20
Healthy volunteers: yes

Brief summary:
The primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of voxilaprevir (formerly GS-9857) in participants with severe renal impairment and matched healthy control participants.

Detailed description:

Arms:
arm 1: Participants will receive a single dose of voxilaprevir on Day 1. arm 2: Participants will receive a single dose of voxilaprevir on Day 1.

Interventions: intervention 1: Voxilaprevir
Intervention descriptions: intervention 1: 100 mg tablet administered orally

Protocol document: